Key result
Active biofeedback did not significantly differ from placebo biofeedback in achieving a systolic pressure reduction of ≥5 mm Hg (39.3% vs 42.9%; P=NS).
Why the study?
Does active biofeedback reduce systolic blood pressure by 5 mm Hg or more compared to placebo biofeedback in untreated mildly hypertensive individuals?
Population
56 untreated, well-characterized, mildly hypertensive individuals
Comparison
Active biofeedback vs Placebo biofeedback
Design
RCT, randomized, double-blind
Follow-up
two laboratory sessions
Authors
Loading...
Biofeedback confers no additional SBP reduction beyond placebo in mild hypertension; challenges efficacy claims and redirects research to other interventions.
RCT (n=56)
Double-blind
Does active biofeedback reduce systolic blood pressure by 5 mm Hg or more compared to placebo biofeedback in untreated mildly hypertensive individuals?
Absolute Event Rate: 39.3% vs 42.9%
p-value: p=NS
Active biofeedback does not provide specific short-term blood pressure-lowering capability beyond the placebo effect in mildly hypertensive individuals.
Hunyor et al. (1997) conducted an RCT in Mild hypertension (n=56). Active biofeedback (continuous pressure feedback) vs. Placebo biofeedback was evaluated on Lowering systolic pressure by 5 mm Hg or more (p=NS). Active biofeedback did not significantly differ from placebo biofeedback in achieving a systolic pressure reduction of ≥5 mm Hg (39.3% vs 42.9%; P=NS).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: